{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["35(24)"],"submitter":["van Geldermalsen M"],"pubmed_abstract":["Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumour cells. Uptake of glutamine and subsequent glutaminolysis is critical for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells. This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes. Pharmacological inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signalling, cell growth and cell cycle progression. Notably, these effects were subtype-dependent, with ASCT2 transport critical only for triple-negativ"],"journal":["Oncogene"],"pagination":["3201-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4914826"],"repository":["biostudies-literature"],"pubmed_title":["ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer."],"pmcid":["PMC4914826"],"pubmed_authors":["van Geldermalsen M","Ritchie W","Holst J","Rasko JE","Deng N","Feng Y","Nagarajah R","Beith JM","O'Toole SA","Gao D","Thoeng A","Wang Q","Harvey K","Bailey CG","Marshall AD","Selinger CI"],"additional_accession":[]},"is_claimable":false,"name":"ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.","description":"Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumour cells. Uptake of glutamine and subsequent glutaminolysis is critical for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells. This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes. Pharmacological inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signalling, cell growth and cell cycle progression. Notably, these effects were subtype-dependent, with ASCT2 transport critical only for triple-negativ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jun","modification":"2026-05-05T14:47:19.584Z","creation":"2019-03-27T02:16:34Z"},"accession":"S-EPMC4914826","cross_references":{"pubmed":["26455325"],"doi":["10.1038/onc.2015.381"]}}